Chris Rock Covers COVID, Voting and ‘Renegotiating’ with the Government in Host Monologue

Chris Rock was the first host of “Saturday Night Live’s” 46th season, and he had a tall order ahead of him. Not only was it the show’s return to Studio 8H for the first time this season, but also for the first time since early 2020, since the coronavirus pandemic shifted the end of their Season 45 production to “at-home” episodes.

Rock walked out on stage in a mask but promptly removed it to deliver his monologue, which started by addressing “the elephant in the room,” that President Donald Trump is in the hospital with COVID.

“My heart goes out to COVID,” Rock said.

He also briefly touched on the new protocols in place in the studio to allow for the show to go on live and in-person. He acknowledged the studio audience, noting they had been checked thoroughly before being let in and that they were all first responders.

Read More

SNL: Chris Rock Covers COVID and Voting in Host Monologue

Chris Rock was the first host of “Saturday Night Live’s” 46th season, and he had a tall order ahead of him. Not only was it the show’s return to Studio 8H for the first time this season, but also for the first time since early 2020, since the coronavirus pandemic shifted the end of their Season 45 production to “at-home” episodes.

Rock walked out on stage in a mask but promptly removed it to deliver his monologue, which started by addressing “the elephant in the room,” that President Donald Trump is in the hospital with COVID.

“My heart goes out to COVID,” Rock said.

He also briefly touched on the new protocols in place in the studio to allow for the show to go on live and in-person. He acknowledged the studio audience, noting they had been checked thoroughly before being let in and that they were all first responders.

Read More

Scholar Rock Presents Data for SRK-015 at the World Muscle Society 2020 Virtual Congress

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep 30, 2020–

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two poster presentations as part of the World Muscle Society (WMS) 2020 Virtual Congress. The SRK-015 clinical development poster will showcase previously presented data from the Phase 1 healthy volunteer trial, as well as baseline characteristics and demographics from the TOPAZ Phase 2 proof-of-concept trial evaluating SRK-015 for the treatment of patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA). The second poster shares data on the pharmacologic effects of SRK-015 in patients with SMA, healthy volunteers, and across animal species.

Details for the two virtual posters at the WMS meeting are as follows:

  • Title: Clinical Development of SRK-015, a Fully Human Anti-proMyostatin Monoclonal Antibody, for the Treatment of Later-Onset Spinal Muscular Atrophy
  • Title: Myostatin
Read More